THE IMMUNE RESPONSE TO INFECTION
Front cover:
Macrophage in the process of engulfing Mycobacterium tuberculosis organisms.

Back cover:
Left (red): Helicobacter pylori; right (blue): Neisseria gonorrhoeae attached to epithelial cells.

All three photos courtesy of Volker Brinkmann and Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology, Berlin, Germany).
# Contents

Contributors / ix
Preface / xv

The Immune Response to Infection: Introduction / 1
STEVEN H. E. KAUFMANN, BARRY ROUSE, AND DAVID SACKS

SECTION I
HOST DEFENSE: GENERAL / 5

1 Invertebrate Innate Immune Defenses / 7
LAURE E. CHAMY, CHARLES HETRU, AND JULES HOFFMANN

2 The Ontogeny of the Cells of the Innate and the Adaptive Immune System / 21
FRITZ MELCHERS

3 The Evolutionary Origins of the Adaptive Immune System of Jawed Vertebrates / 41
JIM KAUFMAN

4 Host Defense (Antimicrobial) Peptides and Proteins / 57
LAURENCE MADERA, SHUHUA MA, AND ROBERT E. W. HANCOCK

5 Reactive Oxygen and Reactive Nitrogen Intermediates in the Immune System / 69
CHRISTIAN BOGDAN

6 Complement in Infections / 85
WILHELM J. SCHWAEBLE, YOUSSEF MOHAMMED ALI, NICHOLAS J. LYNCH, AND RUSSELL WALLIS

7 Immune Defense at Mucosal Surfaces / 97
MARIAN R. NEUTRA AND JEAN-PIERRE KRAEHENBUHL

8 Regulation of Antimicrobial Immunity / 109
YASMIN BELKAID, SHARVAN SEHRAWAT, AND BARRY T. ROUSE

9 Memory and Infection / 121
DAVID MASOPUST AND MARK K. SLIFKA

SECTION II
THE PATHOGENS / 131

10 Overview of Viral Pathogens / 133
JONATHAN W. YEWDELL AND JACK R. BENNINK

11 Overview of Parasitic Pathogens / 143
RICK L. TARLETON AND EDWARD J. PEARCE

12 Overview of Bacterial Pathogens / 155
PHILIPPE J. SANSONETTI AND ANDREA PUHAR

13 Overview of Fungal Pathogens / 165
AXEL A. BRAKHAGE AND PETER F. ZIPFEL

14 Prionoses and the Immune System / 173
JÜRGEN A. RICHT AND ALAN YOUNG

SECTION III
INNATE IMMUNITY TO MICROBIAL INFECTIONS / 183

15 Innate Immunity to Viruses / 185
AKIKO IWASAKI

16 Natural Killer Cell Response against Viruses / 197
JOSEPH C. SUN AND LEWIS L. LANIER
CONTENTS

17  Innate Immunity against Bacteria / 209
    THOMAS ARESCOUG, ANNETTE PLUDEMMANN, AND SIAMON GORDON

18  Innate Immunity to Parasitic Infections / 225
    CHRISTOPHER A. HUNTER AND ALAN SHER

SECTION IV

ACQUIRED IMMUNITY TO MICROBIAL INFECTIONS / 237

19  Acquired Immunity against Virus Infections / 239
    EVA SZOMOLANYI-TSUDA, MICHAEL A. BREHM, AND RAYMOND M. WELSH

20  Immune Responses to Persistent Viruses / 255
    E. JOHN WHERRY AND PAUL KLENERMAN

21  Acquired Immunity: Acute Bacterial Infections / 269
    DENNIS W. METZGER

22  Acquired Immunity: Chronic Bacterial Infections / 279
    ANDREA M. COOPER AND RICHARD ROBINSON

23  Acquired Immunity: Fungal Infections / 289
    LUIGINA ROMANI

24  Acquired Immunity to Intracellular Protozoa / 301
    PHILLIP SCOTT AND ELEANOR M. RILEY

25  Acquired Immunity to Helminths / 313
    DAVID ARTIS AND RICK M. MAIZEUS

SECTION V

PATHOLOGY AND PATHOGENESIS / 325

26  Pathology and Pathogenesis of Bacterial Infections / 327
    WARWICK J. BRITTON AND BERNADETTE M. SAUNDERS

27  Helicobacter pylori: the Role of the Immune Response in Pathogenesis / 337
    KAREN ROBINSON AND JOHN C. ATHERTON

28  Pathogenesis of Helminth Infections / 347
    THOMAS A. WYNN AND JUDITH E. ALLEN

29  Pathology and Pathogenesis of Malaria / 361
    CHANANI AMARATUNGA, TATIANA M. LOPERA-MESA, JEANETTE G. TSE, NEIDA K. MITA-MENDOZA, AND RICK M. FAIRHURST

30  Pathology and Pathogenesis of Virus Infections / 383
    CARMEN BACA JONES AND MATTHIAS VON HERRATH

SECTION VI

EVASION AND SUPPRESSION OF THE ANTIMICROBIAL HOST RESPONSE / 391

31  Viral Immune Evasion / 393
    LILA FARRINGTON, GABRIELA O'NEILL, AND ANN B. HILL

32  Growing Old and Immunity to Viruses / 403
    JANKO NIKOLICH-ZUGICH AND MARCIA A. BLACKMAN

33  Growing Old and Immunity to Bacteria / 413
    JOANNE TURNER

34  Bacterial Strategies for Survival in the Host / 425
    ANNA D. TISCHLER AND JOHN D. MCKINNEY

35  Suppression of Immune Responses to Protozoan Parasites / 441
    DAVID L. SACKS

36  Immune Evasion by Parasites / 453
    JOHN M. MANSFIELD AND MARTIN OLIVIER

SECTION VII

GENETICS OF THE ANTIMICROBIAL HOST RESPONSE / 471

37  Genetics of Antibacterial Host Defenses / 473
    STEVEN M. HOLLAND

38  Immunogenetics of Host Response to Parasites in Humans / 483
    JENEFER M. BLACKWELL

39  Immunogenetics of Virus Pathogenesis / 491
    SEAN WILTS, DAVID I. WATKINS, EMIL SKAMENE, AND SILVIA M. VIDAL

Downloaded from www.asmscience.org by
IP: 54.70.40.11
On: Sat, 29 Dec 2018 08:13:06
<table>
<thead>
<tr>
<th>SECTION VIII</th>
<th>AUTOIMMUNITY AND CANCER / 509</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 Viruses, Autoimmunity, and Cancer / 511</td>
<td>MEGHANN TEAGUE GETTS, LIES BOGAERT, W. MARTIN KAST, AND STEPHEN D. MILLER</td>
</tr>
<tr>
<td>41 The Role of Bacterial and Parasitic Infections in Chronic Inflammatory Disorders and Autoimmunity / 521</td>
<td>STEFAN EHLERS AND GRAHAM A. W. ROOK</td>
</tr>
<tr>
<td>42 Theileria-Induced Leukocyte Transformation: an Example of Oncogene Addiction? / 537</td>
<td>MARIE CHAUSSIEPIED AND GORDON LANGSLEY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SECTION IX</th>
<th>IMMUNE INTERVENTION / 547</th>
</tr>
</thead>
<tbody>
<tr>
<td>43 Systems Vaccinology: Using Functional Signatures To Design Successful Vaccines / 549</td>
<td>TROY D. QUEREC AND BALI PULENDRAN</td>
</tr>
<tr>
<td>44 Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses / 559</td>
<td>BARNEY S. GRAHAM AND CHRISTOPHER WALKER</td>
</tr>
<tr>
<td>45 Immune Intervention Strategies against Tuberculosis / 571</td>
<td>PETER ANDERSEN AND STEFAN H. E. KAUFMANN</td>
</tr>
<tr>
<td>46 Immune Intervention in Malaria / 587</td>
<td>CAROLE A. LONG AND FIDEL P. ZAVALA</td>
</tr>
<tr>
<td>47 Targeting Components in Vector Saliva / 599</td>
<td>MARY ANN McDOWELL AND SHADEN KAMHAWI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SECTION X</th>
<th>THE MAJOR KILLERS (CLINICS, EPIDEMIOLOGY, AND IMMUNE PARAMETERS) / 609</th>
</tr>
</thead>
<tbody>
<tr>
<td>48 AIDS Vaccines: the Unfolding Story / 611</td>
<td>STEPHEN NORLEY</td>
</tr>
<tr>
<td>49 Tuberculosis / 623</td>
<td>GERHARD WALZL, PAUL VAN HELDEN, AND PHILIP R. BOTHA</td>
</tr>
<tr>
<td>50 Malaria: Clinical and Epidemiological Aspects / 633</td>
<td>ANDREA A. BERRY, MYAING M. NYUNT, AND CHRISTOPHER V. FLOWE</td>
</tr>
<tr>
<td>51 The Epidemiology and Immunology of Influenza Viruses / 643</td>
<td>RAFAEL A. MEDINA, IRENE RAMOS, AND ANA FERNANDEZ-SMESA</td>
</tr>
</tbody>
</table>

Index / 653
Contributors

ANDREA A. BERRY
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201

MARCIA A. BLACKMAN
The Trudeau Institute, Saranac Lake, NY 12983

JENEFER M. BLACKWELL
Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Subiaco, Western Australia, Australia

LIES BOGAERT
Departments of Molecular Microbiology & Immunology and Obstetrics & Gynecology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033. Department of Surgery and Anesthesiology of Domestic Animals, Faculty of Veterinary Medicine, University of Ghent, Merelbeke, B-9820, Belgium

CHRISTIAN BOGDAN
Microbiology Institute Clinical Microbiology, Immunology and Hygiene, Friedrich Alexander University Erlangen, Nuremburg, and University Clinic of Erlangen, Wasserturmstrasse 3/5, D-91054 Erlangen, Germany

PHILIP R. BOTHA
Division of Infectious Diseases, Department of Medicine Tygerberg Academic Hospital, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, Tygerberg, 7505, South Africa

AXEL A. BRAKHAGE
Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoll Institute (HKI), Friedrich Schiller University Jena, Department Molecular and Applied Microbiology and Department of Infection Biology, Beutenbergstrasse 11a, 07745 Jena, Germany

MICHAEL A. BREHM
Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01655

WARWICK J. BRITTON
Centenary Institute, Locked Bag No 6, Newtown, 2042; and Discipline of Medicine, Sydney Medical School, University of Sydney (D06), Sydney, 2006, NSW, Australia

YOUSSIF MOHAMMED ALI
Department of Infection, Immunity and Inflammation, University of Leicester, MSB, University Road, Leicester LE1 9HN, United Kingdom

JUDITH E. ALLEN
Institutes of Evolution, Immunology and Infection Research, University of Edinburgh, Edinburgh EH9 3JT, UK

CHANAKI AMARATUNGA
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852

PETER ANDERSEN
Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark

THOMAS ARESCHOUG
Department of Laboratory Medicine, Division of Medical Microbiology, Lund University, Sölvegatan 23, 22362 Lund, Sweden

DAVID ARTIS
Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104-4539

JOHN C. ATHERTON
Nottingham Digestive Diseases Centre Biomedical Research Unit, University Hospital, Nottingham, NG7 2UH, United Kingdom

CARMEN BACA JONES
Center for Type 1 Diabetes Research, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037

YASMINE BELKAID
Mucosal Immunology Unit, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Health, 4 Center Drive B1-28, Bethesda, MD 20892

JACK R. BENNING
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-3209

ASMINE BELKAID
Mucosal Immunology Unit, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Health, 4 Center Drive B1-28, Bethesda, MD 20892

JACK R. BENNING
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-3209
BARRY T. ROUSE  
Department of Pathobiology, College of Veterinary Medicine,  
University of Tennessee, 1414 Cumberland Ave.,  
Knoxville, TN 37996

DAVID L. SACKS  
Laboratory of Parasitic Diseases, National Institutes of  
Allergy and Infectious Diseases, National Institutes of  
Health, Building 4, Room 126, 4 Center Dr., MSC 0425,  
Bethesda, MD 20892-0425.

PHILIPPE J. SANSONETTI  
Unité de Pathogénie Microbiennne Moléculaire, INSERM  
U786, Institut Pasteur, 75724 Paris Cedex 15, France

BERNADETTE M. SAUNDERS  
Centenary Institute, Locked Bag No 6, Newtown, 2042;  
and Discipline of Medicine, Sydney Medical School,  
University of Sydney (D06), Sydney, 2006, NSW, Australia

WILHELM J. SCHWAEBLE  
Department of Infection, Immunity and Inflammation,  
University of Leicester, MSB, University Road,  
Leicester LE1 9HN, United Kingdom

PHILLIP SCOTT  
Department of Pathobiology, School of Veterinary Medicine,  
University of Pennsylvania, Philadelphia, PA 19104

SHARVAN SEHRAWAT  
Department of Pathobiology, College of Veterinary Medicine,  
University of Tennessee, 1414 Cumberland Ave.,  
Knoxville, TN 37996

ALAN SHER  
Laboratory of Parasitic Diseases NIAID, NIH Building 50,  
Room 6140, 50 South Drive, MSC-8003, Bethesda,  
MD 20892-8003

EMIL SKAMENE  
Department of Human Genetics, The McGill Life Sciences  
Complex, Bellini Pavilion, Room 356, 3649 Promenade Sir  
William Osler, Montreal, QC H3G 0B1, Canada

MARK K. SLIFKA  
Vaccine and Gene Therapy Institute, Oregon Health &  
Science University, 505 NW 185th Ave., Beaverton, OR 97006

JOSEPH C. SUN  
Department of Microbiology and Immunology and  
the Cancer Research Institute, University of California,  
San Francisco, CA 94143

EVA SZOMOLANYI-TSUDA  
Department of Pathology, University of Massachusetts  
Medical School, Worcester, MA 01655

RICK L. TARLETON  
Center for Tropical & Emerging Global Diseases,  
Coverdell Center for Biomedical Research (Rm 310B),  
500 D.W. Brooks Drive, University of Georgia,  
Athens, GA 30602

ANNA D. TISCHLER  
Global Health Institute, Swiss Federal Institute of Technology  
(EPFL), CH-1015 Lausanne, Switzerland
THOMAS A. WYNN
Immunopathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892-8003

JONATHAN W. YEWDELL
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-3209

ALAN YOUNG
Department of Veterinary Science, South Dakota State University, Box 2175, ARW168F, Brookings, SD 57007

FIDEL P. ZAVALA
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Malaria Research Institute, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD 21205

PETER F. ZIPFEL
Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute (HKI), Friedrich Schiller University Jena, Department Molecular and Applied Microbiology and Department of Infection Biology, Beutenbergstrasse 11a, 07745 Jena, Germany
Preface

“Excellent textbooks and review volumes on immunology, virology, parasitology, medical microbiology, and infectious diseases abound. So what gap is this book aimed to fill?”

This question was posed in the preface of the ASM Press book *Immunology of Infectious Diseases* (edited by Stefan H. E. Kaufmann, Alan Sher, and Rafi Ahmed), published in 2002. The explanation provided then still holds true today. Microbiology and immunology, despite their common roots, have matured as distinct disciplines, and infectious diseases are too often viewed from the perspective of either the microbe or the host. A more holistic approach was provided by that book and a second one published by ASM Press in 2004, *The Innate Immune Response to Infection* (edited by Stefan H. E. Kaufmann, Ruslan Medzhitov, and Siamon Gordon).

These books now urgently need updating because the knowledge base in immunology, as well as with all types of infectious agents, has expanded dramatically. The present volume, *The Immune Response to Infection*, covers all aspects of innate and adaptive immune mechanisms and describes how they interact with pathogens of different types, resulting in either success or failure to control infection and clinical disease. This volume also emphasizes how our understanding of mechanistic events is leading the design and production of more effective prophylactic and therapeutic control measures for infectious agents.

Most of the chapters here consider host-pathogen interactions in the context of the broad divisions of the microbial world—either viruses, bacteria, or parasites—and do not confine their discussion to any individual pathogen. The exceptions are for the agents of the “big three” infectious diseases—HIV/AIDS, tuberculosis, and malaria—which account for almost one-third of human deaths from infections, as well as influenza, which is the focus of much media and public attention. We have also included chapters that consider the detrimental sequelae of infection that are an indirect result of the infectious process, such as chronic inflammation, cancer, and autoimmunity. Finally, all of the chapters emphasize the special attributes that make pathogens difficult to control, and they appraise the prospects of current and future prophylactic and therapeutic vaccines.

We hope that this book, which comprises the rich variety of aspects of infection and immunity, helps to further promote the important relationship between immunology and medical microbiology. We express our deep appreciation to the editorial staff of ASM Press, in particular, Greg Payne and Ellie Tupper. We also want to thank our associates Mary Louise Grossman and Lisa Washington for their secretarial help and for their wonderful dedication. Most of all, we thank our colleagues for sacrificing so much of their valuable time to generously share their outstanding expertise with us and with the readers of this book.

STEVEN H. E. KAUFMANN, BARRY T. ROUSE, AND DAVID L. SACKS
Endocarditis, 414t
in animal models of aging, 419t
human studies of, 420t
Endogenous Treg, 115
Endoplasmic reticulum (ER), 134
ENL. See Ertryhma nodosum leprosum
Entamoeba histolytica, 226
Enterobacteriaceae, 215, 222
Entomological inoculation rate (EIR), 638
Epidermodysplasia verruciformis (EV), 518
Epidermal growth factor receptor (EGFR), 63
Eosinophils, 210, 316
Eosinophil granule protein (ECP), 221
ENU.

Endocarditis, 414t
in animal models of aging, 419t
human studies of, 420t

Extracellular polymetric substances
Extracellular persistence, 429–430

Evasion, of parasitic infections, 149

Epitope spreading, 515

Erythema nodosum leprosum (ENL), 333
ERK-1/2, 63
ERAAP, 42

FAD.

Factor C, 15
Factor H-like protein (FHL-1), 89, 169
FAD. See Flavin adenine dinucleotide
FADD. See Fas-activation death domains
FAE, 102
Facalbacterium prausnitzii, chronic inflammatory disorders and, 527t
Fas-activation death domains (FADD), 246
Fasl. See Fas ligand
Fas ligand (Fasl.), 205
Fatal familial insomnia (FFI), 173
Fibrin
Fc, 3
Fe gamma, 216
FeR, 30
FeRn, 105
FDC. See Follicular dendritic cells
Ffi. See Fatal familial insomnia
FHA. See Filamentous hemagglutinin (FHA)
FFI-1. See Factor H-like protein
Fibrinogen-related proteins (FREPs), 16
Fibrogen-related proteins (FREPs), 43
L-Ficolin, 89
Filamentous hemagglutinin (FHA), 111, 112, 434
Filaviruses, 361
Fimbriated bacteria, 526
Fimcutes, 156
chronic inflammatory disorders and, 527t
FIZZ molecule, 351
Flagellin, 212
Flaialneme, chronic inflammatory disorders and, 527t
Flavin adenine dinucleotide (FAD), 74
Flavin mononucletide (FMN), 74
Flaviviridae, 193, 385
FLICE protein, 395
FLT3L, 33
FMDV. See Foot and mouth disease
FMN. See Flavin mononucletide
FNGN. See Focal necrotizing glomerulonephritis
Focal necrotizing glomerulonephritis
Follicular dendritic cells (FDC), 127, 174, 175, 176, 177
Foodborne infection, 414t
in animal models of aging, 419t
in elderly, 417–418
human studies of, 420t
Foot and mouth disease (FMDV), 395
Foxxp1, 109, 112, 117, 444, 447
FPRL-1, 63
Fracastoro, Girolamo, 1
Filamentous hemagglutinin (FHA), 111, 175, 176, 177
Flaviviridae
Filoviruses, 561
G6PD deficiency, malaria and, 370–371
GALD, 50
Galactin 3, 147, 148, 151
GALD. See Galactosylphosphatidylinositol (GPI)
GALT. See Gut-associated lymphoid tissue
GALT-associated B-cell compartments, 32
GAS. See Group A streptococci
Gastritis, patterns of, 338f
Gastrointestinal tract, acquired immunity in, 314–317
GATA-2, 241
GATA-3, 282, 316
GBS. See Guillain-Barré syndrome
GCSF, 475
GDI. See GDP-dissociation inhibitor
GDP-dissociation inhibitor (GDI), 72
Genetic diversity, 560–561
Generic effects, measuring, 484–485
Genetic vaccines, AIDS, 613–614
Gene transcription, iNOS, 77
Genome-wide linkage scans (GWLS), 484, 4876

Leishmania, 487t
Germal centers
antigen maintenance in, 176–177
PrP maintenance in, 177
Gerstmann-Straussler-Scheinker syndrome (GSS), 173
GFI. See Growth factor independent-1
Giardia lamblia, 78
GIL4, 495
Ginglymostoma cirratum, 48, 50
GIP. See Glycosylphosphatidylinositol (GPI)
GIP. See Glycophosphatidylinositol (GPI)
Glycolipid, 42
Glycophosphatidylinositol (GPI), 230, 302, 305, 372, 592
Glycoprotein 160 (gp160), 105
Glycosylphosphatidylinositol (GPI), 459
GM-CSF. See Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Glycolytic enzymes, 329
Glycolytic pathway enzymes, 329
Glycophosphatidylinositol (GPI), 459
Glucocorticoid receptor (GR), 348
Glucose-6-phosphatase catalytic subunit 3 (G6PC3), 475
Glucose phosphate isomerase (GPI), 538
GLURP antigens, 592
Glutamic acid, 50
Glycosylphosphatidylinositol (GPI), 443
Glycan, 289
Group A streptococci (GAS), 193, 524
Growing old. See Aging
Group A streptococci (GAS), 193, 524
Growing old. See Aging
Growth factor independent-1 (GFI), 475
GSS. See Gerstmann-Straussler-Scheinker syndrome
GTPase, 228
Guillain-Barré syndrome (GBS), 334, 526
Campylobacter jejuni and, 526
Gut-associated lymphoid tissue (GALT), 20, 31, 528
GWLS. See Genome-wide linkage scans

H1N1 virus, 645
Origin of, 648f
H3K4me3, 115
Latent tuberculosis infection, 625
L-chain loci, 31
LCMV. See Lympohcytoma choriomeningitis virus
Lectin-like receptors, 216
Lectin pathway, 87
deficiencies, 90
helminths and, 351–352
recognition molecules, 87
specific serine proteases, 87–88
structure of, 87
Leeuwenhoek, Antonius van, 2
Legionella
in animal models of aging, 419:
human studies of, 420
Legionella pneumophila, 155, 213, 218, 219,
414, 418, 431
Leishmania
downstream regulatory events, 464
DTH and, 601–602
GLWS, 487t
immune evasion by, 461–465
protective immune response, 601–602
Leishmania braziliensis, 445
Leishmania donovani, 78, 113, 147, 149,
226, 227, 228, 301, 304
DC and, 442t
Leishmania major, 282, 284
DC and, 442t
Leishmania mexicana, 464
Leishmaniasis
Cutaneous, 599
immune suppression and, 445–446
sand flies, 600
visceral, 485
LEKT1. See Lymphoepithelial Kazal-type trypsin inhibitor
Leprosy, pathology of, 333–334
Leucine rich repeats (LRRs), 8, 44, 219, 234
Liver stage specific antigen-1 (LSA-1), 306
Live attenuated virus vaccines, 612
Liver stage specific antigen-1 (LSA-1), 306
LJM19, 600
Lipids, 212
Lipoteichoic acid (LTA), 58, 212, 214
Lipophosphoglycan (LPG), 226, 302
Lipopolysaccharides (LPSs).
Malaria, 305–308. See also Plasmodium
blood-stage parasites, 501
cerebral, 366–367
coonfections, 639
control, 639
cDC and, 442t
elimination, 639
epidemiology, 636–639
erhymocytic-stage, vaccines, 590–593
G6PD deficiency, 370–371
hematopoiesis and, 368
HIV, 367
immune intervention in, 587–595
immunology, 636–639
inflammation in, 365
initiation, 305–306
innate immunity, 639
integrated view of, 375–376
life cycle of, 589f, 633–634
metabolic acidosis and, 368
microvascular obstruction in, 365
mortality, 638f
non-falciparum, 636
non-falciparum, 636–637
parasites, 501
cooxidation, 501
rectal, 636–367
infections, 639
control, 639
DC and, 442t
elimination, 639
epidemiology, 636–639
erythrocytic-stage, vaccines, 590–593
G6PD deficiency, 370–371
hematopoiesis and, 368
HIV, 367
immune intervention in, 587–595
immunology, 636–639
inflammation in, 365
initiation, 305–306
innate immunity, 639
integrated view of, 375–376
life cycle of, 589f, 633–634
metabolic acidosis and, 368
microvascular obstruction in, 365
mortality, 638f
non-falciparum, 636
NEP, See Nuclear export protein
Nephritis-associated streptococcal plasmin receptor (NAP1), 330
Netherton syndrome, 480
NETs. See Neutrophil extracellular traps
Neuraminidase, 643
Neutrophil extracellular traps (NETs), 72
Neutrophil granule formation defects, 476
Neutrophil oxidative metabolism defects, 476
Neutrophils, 210
in extracellular bacterial infection, 328–329
saliva and, 602
Neutrophil serine proteases, 219–220
Neuropathy, 8
Ornithine aminotransferase (OAT), 351
Ornithine aminotransferase (OAT), 351
Ornithine decarboxylase (ODC), 351
Ornithine decarboxylase (ODC), 351
Ornithine decarboxylase (ODC), 351
Orthomyxoviridae, 193
Orthomyxovirus resistance genes, 193–194
Outer inflammatory protein gene A (oLP), 464
OVA. See Ovalbumin
Ovalbumin (OVA), 149, 602
Ox40, 243
P2X7, 63
P36-7, 451
P13-K. Theileria and, 541
P53, 394F
p50, 191
P554S, 497
PA, epitope, 405
PACRG, 286
Pal. See Pathogenicity islands
PAMP. See Pathogen-associated molecular patterns
PAMP agonists, 577
PANDAS. See Pediatric autoimmune neuropsychiatric disorders associated with streptococci
Paneth cells, 211
Paralogs, 44
Parasite-encoded antigens, 593
Parasitemia, asymptomatic, 363
Parasite-targeted oncogenic pathways, 540–541
Parasitic infections
adaptive immunity and, 231–232
clonality, 149
chronicity, 149
evasion, 149
host response to, 483–488
immunity evasion by, 453–465
innate immunity to, 223–232
regulatory responses in, 232
Parasitic pathogens, 143–151
clonality, 149
diseases caused by, 143–147
evasion, 149
immunity to, 147–148
persistent, 149
relationship between immunity and disease in, 149–150
Parasitophorous vacuole (PV), 143
PARC2, 286
Parvovirus B19
response to, 493–494
susceptibility loci, 504
Pautier, Louis, 2
Pathogen-associated molecular patterns
(PAMP), 110, 157, 188, 219, 352
Pathogenicity islands (Pal), 339–340
Pattern recognition molecules (PRM), 231
Pattern recognition receptors (PRR), 230, 291, 305, 425
Helicobacter pylori and, 341–342
expression of, 26
PB1, 405
P Blood group antigens, 494
PBCs. See Peripheral blood mono-nuclear cells
PCD. See Primary ciliary dyskinesia
PD-1, 259
pDC. See Plasmacytoid dendritic cells
PDC-E2, 526
PDL. See Protein disulfide isomerase
Pediatric autoimmune neuropsychiatric disorders associated with streptococci (PANDAS), 525
Peptide-loading complex (PLC), 42
Peptidoglycan (PGN), 8, 158, 159, 212
IMD pathway and, 9
Toll pathway and, 9
Peptidoglycan recognition proteins (PRGRs), 8, 213, 220
Perforin, 205
Peripheral blood mononuclear cells (PBMCs), 364, 419, 497, 538
Peripheral memory T-cells, 406
Peripheral tissue, T-cell invasion of, 246
Peroxisome, 64
Persistence, of parasitic infections, 149
Persistent infections, 522–523
response to, 524
Persistent viruses, 255–265, 407–410
latent, 407–409
memory T-cell differentiation during, 418–419
pathology, 255–256
strategies of, 256
Peyer's patch, 175, 350
PBM1, 144, 364, 365–366, 442, 591, 634
P625, 594
P623, 594
PG. See Phosphatidylglycerol
PGF2, See Prostaglandin E2
PON. See Peptidoglycan
PGMRs. See Peptidoglycan recognition proteins
Phagocyte, 69
Antimicrobial effector mechanisms, 70
innate defenses mediated by, 227–228
Phagocytosis, 15
bacterial pathogens, 213
Drosophila, 14
responses to, 213
Phase variation, 427
Neisseria gonorrhoeae, 427, 428f
Phenol-Auramine, 627
Phenoloxidase (PO), 14
ROI, 70–71
PHIST domain, 594
Phlebotomus papatasi, 602
Phosphatidyl glycerol, 433
Phosphatidylinositol-3-kinase (PI3-K), 63
Phosphatidylinositol-3-kinase
AKT-mTOR pathway, 33
Phosphoryrinosine kinase (PITK), 461
Phox, 72
hSCs. See Pluripotent hematopoietic stem cells
Phylaxia, 93
PI3-K. See Phosphatidylinositol-3-kinase
Piconoviridae, 193
PKA, Theileria and, 541
PKC. See Protein kinase C
PKDL. See Post-kala-atar dermal leishmaniasis
PKR. See Protein kinase R
Plagues, 1
Plasma cells, 125, 241
Plasmacytoid dendritic cells (pDC), 211
Plasmodium, 301, 464, 589
OLWS, 487f
life cycle of, 362f
preerythrocytic stages of, 588
Plasmodium berghei, 15, 148, 226
Oligodeoxynucleotides (ODN), 447
OlpA. See Outer inflammatory protein gene A
OmpA, 212
Onchocerca volvulus, 146
Ornithine aminotransferase (OAT), 351
Ornithine decarboxylase (ODC), 351
ORs. See Odd ratios
Orthomyxoviridae, 193
Orthomyxovirus resistance genes, 193–194
Outer inflammatory protein gene A (oLP), 464
Plasmodium chabaudi, 442, 591
Plasmodium falciparum, 229, 308, 441
development of, in human red blood cells, 590f
human genetic resistance to, 369–370
liver stages of, 587–590
multiplication rate, 364
pathogenesis, 363–369, 376f
sporozoites, 587–590
Plasmodium knowlesi, 636
Plasmodium ovale, 636
Plasmodium relictum, 371–375, 587, 636
anemia and, 372
cavovascular complexes, 373
severe infections, 374
thrombocytopenia and, 372
Plasmodium yoelii, 113
PLC. See Peptide-loading complex
Pluripotent hematopoietic stem cells
(PHSCs), 23
PLZF, 28
PMCA, 179
PMN, 210
PM2, 212
Pmy, 53
Prokaryotic ubiquitin-like protein (PUP), 432
Progenitor cells, 26
Pneumococcal cell wall, 91
Pneumococcal cell-surface proteins, 91
Pneumococcal surface protein A (PspA), 92
Pneumocystis carinii, 636
Pneumolysin, 91
Pneumolysins, 173–178
Pneumonectomy, 636
Pneumovirus, 27
Post-streptococcal glomerulonephritis, 330
Postexposure vaccination, 578–579
Porifera, 143
Polysaccharide, 275
Polyomavirus and cancer, 519
Polymeric peptidoglycan, 212
PO, 64
PoxP. See Poxvirus vectors
Poxviruses, 614
PPAR gamma, 99, 348
Purified recombinant protein vaccines, 612
Purified recombinant protein vaccines, 612
Putrefaction, 2
PV. See Parastaphylococci vacule
Pyrexia, 222
pX protein, 394
PYD-containing subfamily, 189
Quiescent intracellular reservoirs (QIRs), 434
RA. See Rheumatoid arthritis
Rac2, 177
RAC2 deficiency, 478
RAGE, 41, 191
RAR, 101, 157, 159, 161, 273
R determinant
RBC, 636
RBCs, 636
RAG, 25, 31, 45
RAG1, 27, 41
RAG2, 25, 27, 41
RALDH2, 530
RANTES, 500
Rapidly growing intracellular bacteria, 331
RBC. See Red blood cell
RBG30, 580
Reactive nitrogen intermediates (RNI), 69, 71
generation of, 75–76
perspective, 79
Reactive oxygen intermediates (ROI), 69–75
function of, 74
generation of, 70–71
immunomodulation, 74
NOX/DUOX family and, 72
perspective, 79
phenoxydases, 70–71
signaling, 74
Reactive oxygen species (ROS), 8, 432f
Receptor interacting protein 1 (RIP1), 11
Recombinant vector vaccines, 612
for AIDS, 614
Recombination signal sequences (RSS), 45
Red blood cell (RBC), 301
polymorphisms, 375
Ref2, 10
Regulatory B-cells, 530
Regulatory macrophages, 530
Regulatory T-cells, 343
in chronic inflammatory disorders, 529
in fungal infections, 295f
immune suppression and, 443–446
subsets of, 444f
Relapsing malaria, 636
REL factors, 15
RELCH, 351
Reoviridae, 193
Repetitive vectors, 617
RER. See Rough endoplasmic reticulum
Respiratory distress, malaria and, 368
Respiratory syncytial virus (RSV), 112, 385, 559
vaccine development, 567
Respiratory viruses, 404–405
aging and, 405
Restriction fragment length polymorphism (RFLP), 538
Retinoic acid-induced protein 1 (RIG-1), 495, 521
Retroviridae, 193
RFLP. See Restriction fragment length polymorphism
Rhazes, 1
RHD. See Rheumatic heart disease
Rheumatic heart disease (RHD), 334
Rheumatoid arthritis (RA), 30
Rhipicephalus appendiculatus, cement protein
64TRP from, 604
Rickettsia prowazekii, 155
Rifaximin, 627
RIG-I. See Retinoic acid-induced protein 1
RIG-I, 189
Rig-I-like receptors
RIG-I, 385, 559
RIFL, 538
RILP. See Retinoic acid-induced silencing complex
RIP1. See Receptor interacting protein 1
RISC. See RNA-induced silencing complex
RNA-induced silencing complex
RIP2. See Retinoic acid-induced silencing complex
RIPA, 538
RNA interference (RNAi), 12, 150, 191
RNase A, 221
RNase L, 193
RNase. See Reactive nitrogen intermediates
ROL. See Reactive oxygen intermediates
ROTY, 303
ROS. See Reactive oxygen species
Rough endoplasmic reticulum (RER), 217
RTS,S, 588
Rubella, 125–126
RUT1, 575
Rv3407f, 578
Saliva. See Vector saliva
Salivary proteins, 604
immunization with, 604–605
Salivary vaccines, 604
candidates, 605f
Salmonella, 101, 157, 159, 161, 273
chronic inflammatory infections and, 527f
in elderly, 418
serotypes, 426
Salmonella enterica, 219
Salmonella enterica serovar Typhi, 428
Salmonella enterica serovar Typhimurium, 428
Salmo salar, 50
Salp25, from Salmo salar, 601
Salp25, from Salmo salar, 603
Sample size, 485
Sand flies, 599–602
liver stages of, 587–590
neutralizing effects of, saliva, 600–601
saliva, 599–602
SAP. See Secreted asparyl proteinases;
Serum amyloid protein
Sarcoidosis, 524
SARS. See Severe acute respiratory syndrome
SCARF1, 167
Scavenger receptors, 14, 212, 215, 216, 459
Toxic shock syndrome (TSS), 330
Th17, 103, 112, 148, 241, 329, 343, 384t, 522
in fungal infections, 293–295
helminths and, 352
Tregs and, 529–530
viral pathology and, 385
Theileria, 537–544
activated signaling pathways in, 542f
AKT and, 541t
AP-1 and, 541t
CK2 and, 541t
c-Myc and, 541t
E2F and, 541t
Hck and, 541t
host and parasite interplay, 537–538
host cell information tracking, 541–544
immunization against, 538
JAK and, 541t
JNK and, 541t
NOTCH-CSL and, 541t
P13-K and, 541t
sporozoites, 537–544
STAT-3 and, 541t
TMEV and, 513
Tregs and, 529–530
helminths and, 352
in fungal infections, 293–295

Toxocara canis, 229
Toxoplasma, 144, 147, 301, 304
Toxoplasma gondii, 105, 228, 231, 487
tPA. See Tissue type plasminogen activator
TyrK, 428
Tri1 cells, induction of, 110–111
TRAF, 16
TRAF2, 8
TRAF3, 186
TRAF6, 186
TRAIL, 203, 205
Transcription controls, 25
Transforming growth factor beta (TGF-β), 109–110, 317
Transmissible mink encephalopathy (TME), 173
Transmissible spongiform encephalopathies (TSEs), 173
Transmission disequilibrium test (TDT), 484
TRAP. See Thrombospordin-related adhesive protein
Trefoil factor 3 (TFF3), 319
Treg, 109–110, 149, 344
during acute infections, 112–113
adjuvants, 529
boosting, 116
during chronic infections, 113–114
dendritic cells and, 446–448
endogenous, 115
fungal infections and, 295–296
manipulating, 115–117
modulating responses, 111
negative control of, 115
plasticity, 115
Th17 and, 529–530
Treponema pallidum, 155, 427–428
T richikellia, 229
T richinella spiralis, 320
chronic inflammatory disorders and, 527t
T richostrongylus orientalis, 147
T richurius, 229, 352
T richuris suis, chronic inflammatory disorders and, 527t
T richuris trichiura, 146, 229
GIWS, 487
TRIF, 231, 563
TRIM5a, 194
TRIM genes, 48
Trypanolytic factor, 227
Trypanosoma, 464
Trypanosoma cruzi, 226–227
Trypanosoma cruzi, 525–526
DC and, 442t
Trypanosoma antigentic variation, 454–455
Trypanosoma lysis factor (TLF1), 227
Trypanosoma virulence, 460–461
TSEs. See Transmissible spongiform encephalopathies
TSLF. See Thymic stromal lymphoprotein
TSS. See Toxic shock syndrome
TST. See Tuberculin skin test
Tuberculosis (TB), 1, 414t, 418, 483
acquired immunity and, 572–573
active, 627
in animal models of aging, 419t
attenuated parasite vaccines, 589–590
biomarkers, 628–630
clinical trials, 580–581
drug-resistant, 624
DNA and, 537–534
epidemiology of, 623–624
extensively drug resistant, 627–628
future vaccination strategies, 579–580
HIV-associated, 623–624
human studies of, 420t
immune intervention strategies against, 571–582
latent, 625
memory and, 573
mortality, 623
pathogenesis of, 625–626
pathology of, 332–333
postexposure vaccination, 578–579
progression of, 624
spread of, 624
stopping, 627–628
strategies against, 574–575
subdominant epitopes, 579
suppression, 573
vaccine candidates, 577t
vaccine construct design, 588–589
Tumor necrosis factor (TNF), 7
Trypanosome lysis factor (TLF1), 227
Trypanosome antigenic variation, 454–455
Trypanosoma cruzi, 145, 427–428
UPEC, 491
Ureaplasma urealyticum, 463
Uncomplicated malaria, 362, 635
UniProt, 60
Urinary tract infection (UTI), 413, 414t
Vaccine(s)
AIDS, 611–618
attenuated parasite, 589–590
candidates for TB, 577t
cellular immunity and, 564
chips, 554
development of, for HIV, 562–565
development of, for RSV, 567
DNA, 578, 614
dendritic cells and, 446–447
evolution of, 568f
functional signatures and, 555
genetic, 613–614
humoral immunity and, 565–566
influenza, 649
liver, 650
live attenuated virus, 612t
malaria, 590–594, 639–640
mucosal, 105
multitargeted subunit, 589
V-Ah immune complex formation. See Virus-antibody immune complex formation
Vaccine(s)
AIDS, 611–618
attenuated parasite, 589–590
candidates for TB, 577t
cellular immunity and, 564
chips, 554
development of, for HIV, 562–565
development of, for RSV, 567
DNA, 578, 614
dendritic cells and, 446–447
evolution of, 568f
functional signatures and, 555
genetic, 613–614
humoral immunity and, 565–566
influenza, 649
liver, 650
live attenuated virus, 612t
malaria, 590–594, 639–640
mucosal, 105
multitargeted subunit, 589
Vaccine(s) (continued)
new construct design, 588–589
postexposure, 578–579
preexposure, 575–576
prion, 178–179
protein subunit, 576–577
purified recombinant protein, 612
recombinant vector, 612t, 614
RSV, 567
salivary, 604, 605t
signaling networks, 552–554
specialized tissue and, 566–567
subunit, 613
therapeutic, 616–617
traditional, 611–612
 transmission-blocking, 593–594
virus-like particle, 612
 whole cell, 593
 whole inactivated virus, 612t
 Vaccinia, 125–126
 Vaccinia virus (VV), 239
 Vaccinology, 549–555
 systems, 554
 Vacuolating cytotoxin (VacA), 340
 T-cell function and, 436–437
 VAR2CSA, 368, 369, 593
 var genes, 365–366
 Variable lymphocytes receptor (VLR), 17, 44
 Variable region-containing chitin-binding protein (VCBP), 46
 Variant antigenic type (VAT), 454
 Variant surface glycoprotein (VSG), 145, 445, 455–456, 460
 specific T cells, 456–457
 Varicella zoster virus (VZV), 125–126,
 aging and, 407
 VariVax, 407
 Varro, Marcus Terentius, 1
 VAT. See Variant antigenic type
 V-ATPase, 431
 VCBP. See Variable region-containing chitin-binding protein
 VDAC1, 644
 VDJ, 27
 VDR. See Vitamin D receptor
 Vectors. See specific vectors
 Vector saliva
 immunological memory and, 604
 neutrophils and, 602
 polymorphism, 604
 targeting components in, 599–606
 Vesicular stomatitis virus (VSV), 186,
 497, 602
 V genes, 45
 Vibrio cholerae, 101, 162
 Viperine, 194
t gene, 373
 Viral immune evasion, 393–400
 of apoptosis, 399–400
 of CD8 T cells, 400
 evolutionary considerations, 399–400
 of IFN, 399
 Viral immunity
 adaptive, 404
 age and, 403–410
 innate, 403–404
 LCMV, 407
 Viral infection. See also Persistent viruses
 acquired immunity against, 239–251
 antigen presentation and, 242–243
 complement system in, 93
 control of, by antibodies, 249–250
 heterologous immunity in, 251
 pathology of, 383–388
 Viral pathogens. See also specific pathogens
 classification of, 134
 detection by APCs, 199–201
 difficult, 559–568
 diseases associated with, 134
 entry strategies, 135–136
 genetic instability of, 136–137
 immune attack and, 140–141
 infection sites, 138–139
 innate immunity of, 185–194
 outcomes of infection by, 136
 pathogenicity, 140
 species specificity, 137–140
 structural properties, 133–135
 tissue tropism, 137
 Viral vectors, 577–578
 Virulence factors, 159–161
 interactions between, 340
 transmission, 159
 Virus-antibody (V-Ab) immune complex formation, 385
 Virus entry, genetic control of, 492–495
 Virus-induced autoimmunity, 387–388
 Virus-induced immunopathology, 384–385
 Virus-induced tissue damage, 383
 Virus-like particle vaccines, 612
 Virus-pathogenesis
 immunogenetics of, 491–506
 mouse genetics, 492
 susceptibility loci, 504t
 Virus-specific T-cell epitopes, 242
 activation of, 244–245
 Visceral leishmaniasis (VL), 485, 599
 Vitamin D3, 61
 Vitamin D receptor (VDR), 332
 Vivax malaria
 genetic resistance to, 375
 pathogenesis of, 371
 reticulocytes and, 371–372
 severe, 374
 VL. See Visceral leishmaniasis
 VLR. See Variable lymphocytes receptor
 von Behring, Emil, 3
 VSG. See Variant surface glycoprotein
 VSV. See Vesicular stomatitis virus
 V to J rearrangements, 28
 VV. See Vaccinia virus
 VZV. See Vesicular stomatitis virus
 Warren, Robin, 337
 Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM), 475
 West Nile virus (WNV), 239, 406–407,
 493, 602
 susceptibility loci, 504
 YFV. See Yellow fever virus
 YM-1, 318
 ZAP-70, 32